晨化股份(300610.SZ):子公司擬投資建設年產35000噸烷基糖苷擴建項目
格隆匯6月6日丨晨化股份(300610.SZ)公佈,根據公司戰略規劃,為提升產品競爭實力和市場競爭優勢,擴大市場份額,基於對烷基糖苷市場的長期看好,公司計劃擴大烷基糖苷產能。公司擬以全資子公司淮安晨化新材料有限公司(簡稱“淮安晨化”)為建設主體,投資建設年產35,000噸烷基糖苷擴建項目,建成後公司烷基糖苷年產能達70,000噸。該項目已取得淮安市工業和信息化局簽發的《江蘇省投資項目備案證》,項目總投資1.2億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.